Acquisition ImpactThe recent acquisition of Cerevel and its lead asset Emraclidine is positively impacting the outlook for Abbvie.
Earnings And GuidanceAbbVie beat on both the top and bottom line for the quarter, leading to management raising its 2024 EPS guidance by 1%.
Growth DriversStrong Immunology and Oncology performance, with key drugs like Humira, Rinvoq, Skyrizi, and Imbruvica exceeding consensus estimates.